Clinical Efficacy and Safety of Mesenchymal Stem Cells for Systemic Lupus Erythematosus

Table 2

Meta-analysis of the efficacy of MSC in the therapy of patients with lupus nephritis (RCT).

Indicators	Time point	Studies	test	Model	OR/WMD
		Number	value	Selected	(95% CI)
Proteinuria	2 months	1	—	Fixed	-1.74 (-5.00, 1.52)	0.30
	3 months	1	—	Fixed	-0.92 (-1.05, -0.79)	<0.00001
	6 months	2	0.84	Fixed	-2.00 (-3.81, -0.19)	0.03
	12 months	2	<0.00001	Random	-0.46 (-1.37, 0.45)	0.33
Scr	3 months	1	—	Fixed	-2.52 (-8.53, 3.49)	0.41
	6 months	1	—	Fixed	3.92 (-8.55, 16.39)	0.54
	12 months	2	0.05	Random	-0.74 (-14.04, 12.56)	0.91
Serum albumin	3 months	1	—	Fixed	7.85 (5.93, 9.77)	<0.00001
	12 months	2	0.15	Fixed	0.94 (-0.53, 2.40)	0.21
C3	3 months	1	—	Fixed	0.28 (0.16, 0.40)	<0.00001
	12 months	2	0.02	Random	0.36 (-0.08, 0.79)	0.11
C4	3 months	1	—	Fixed	-0.01 (-0.04, 0.02)	0.46
	12 months	2	0.31	Fixed	-0.01 (-0.03, 0.01)	0.39
SLEDAI	2 months	1	—	Fixed	-6.25 (-9.04, -3.46)	<0.0001
	3 months	1	—	Fixed	-0.89 (-2.19, 0.41)	0.18
	6 months	1	—	Fixed	-4.25 (-6.78, -1.72)	0.001
	12 months	2	0.004	Random	-1.00 (-3.13, 1.14)	0.36
Adverse events	—	2	0.66	Fixed	0.26 (0.07, 0.89)	0.03